Effectiveness of FDG-PET/CT for evaluating early response to induction chemotherapy in head and neck squamous cell carcinoma: A systematic review

Medicine (United States)

Volumn 95, Issue 32, 2016, Pages

  Dos Anjos, Renata Fockink ^a   Dos Anjos, Dalton Alexandre ^a   Vieira, Danielle Leal ^b   Leite, André Ferreira ^c   Figueiredo, Paulo Tadeu De Souza ^c   De Melo, Nilce Santos ^c  

^a HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^b Faculty of health Sciences   (Brazil)

^c UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

FDG PET CT; head and neck cancer; induction chemotherapy; systematic review

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CHECKLIST; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COCHRANE LIBRARY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INDUCTION CHEMOTHERAPY; MEDLINE; PRIORITY JOURNAL; REVIEW; SCIENCEDIRECT; SURVIVAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEB OF SCIENCE; CARCINOMA, SQUAMOUS CELL; DIAGNOSTIC IMAGING; HEAD AND NECK NEOPLASMS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; TREATMENT OUTCOME;

EID: 84983467324     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004450     Document Type: Review

References (52)

1. Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008;371:1695-709
2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108
3. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
4. Lassen P. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010;95:371-80
5. Rohde M, Dyrvig AK, Johansen J, et al. 18F-fluoro-deoxy-glucosepositron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and metaanalysis. Eur J Cancer 2014;50:2271-9
6. Yoo J, Henderson S, Walker-Dilks C. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. Clin Oncol (R Coll Radiol) 2013;25:e33-66
7. Newbold K, Powell C. PET/CT in radiotherapy planning for head and neck cancer. Front Oncol 2012;2:189
8. Minn H, Suilamo S, Seppala J. Impact of PET/CT on planning of radiotherapy in head and neck cancer. Q J Nucl Med Mol Imaging 2010;54:521-32
9. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of posttreatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011;38:2083-95
10. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76
11. Cohen EE, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 2014;32:2735-43
12. Kikuchi M, Nakamoto Y, Shinohara S, et al. Early evaluation of neoadjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma. Int J Clin Oncol 2013;18:402-10
13. Powell C, Schmidt M, Borri M, et al. Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. Radiother Oncol 2013;106:112-7
14. Abgral R, Le Roux PY, Rousset J, et al. Prognostic value of dual-timepoint 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma. Nucl Med Commun 2013;34:551-6
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47
16. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(suppl 1):122S-50S
17. Liu Y, Litière S, Vries EG, et al. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. Eur J Cancer 2014;50:260-6
18. Alonzi R, Hoskin P. Functional imaging in clinical oncology: magnetic resonance imaging-and computerised tomography-based techniques. Clin Oncol (R Coll Radiol) 2006;18:555-70
19. Yaghmai V, Miller FH, Rezai P, et al. Response to treatment series: part 2, tumor response assessment-using new and conventional criteria. AJR Am J Roentgenol 2011;197:18-27
20. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65
21. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-10
22. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362-70
23. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53
24. Bussink J, Herpen CM, Kaanders JH, et al. PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol 2010;11:661-9
25. Pignon JP, leMaitre A, Maillard E, et al. GroupM-NC, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92:4-14
26. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced headand-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:571-8
27. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336-41
28. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007;36:666-76
29. Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015;8:2-10
30. Helfand M, Balshem H. Principles in Developing and Applying Guidance. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD:AHRQ Methods for Effective Health Care; 2008
31. Abgral R, Le Roux PY, Keromnes N, et al. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma. Eur J Nucl MedMol Imaging 2012;39:1839-47
32. Gavid M, Prevot-Bitot N, Timoschenko A, et al. 18F-FDG PET-CT prediction of response to induction chemotherapy in head and neck squamous cell carcinoma: preliminary findings. Eur Ann Otorhinolaryngol Head Neck Dis 2015;132:3-7
33. Kikuchi M, Shinohara S, Nakamoto Y, et al. Sequential FDG-PET/CT after neoadjuvant chemotherapy is a predictor of histopathologic response in patients with head and neck squamous cell carcinoma. Mol Imaging Biol 2011;13:368-77
34. Semrau S, Haderlein M, Schmidt D, et al. Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: what are the best predictors of remission and prognosis? Cancer 2015;121:1214-22
35. Yu J, Cooley T, Truong MT, et al. Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters. J Med Imaging Radiat Oncol 2014;58:18-24
36. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82
37. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-30
38. Schinagl DA, Vogel WV, Hoffmann AL, et al. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69: 1282-9
39. d'Arcy JA, Collins DJ, Padhani AR, et al. Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. Radiographics 2006;26:621-32
40. Kumar R,Mukherjee A,Mittal BR. Special techniques in PET/computed tomography imaging for evaluation of head and neck cancer. PET Clin 2016;11:13-20
41. Mehanna H, Wong WL, McConkey CC, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med 2016;374:1444-54
42. Sheikhbahaei S, Taghipour M, Ahmad R, et al. Diagnostic accuracy of follow-up FDG PET or PET/CT in patients with head and neck cancer after definitive treatment: a systematic review and meta-analysis. AJR Am J Roentgenol 2015;205:629-39
43. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-55
44. Cheebsumon P, YaqubM, van Velden FH, et al. Impact of [(1)(8)F]FDG PET imaging parameters on automatic tumor delineation: need for improved tumor delineation methodology. Eur J Nucl MedMol Imaging 2011;38:2136-44
45. Romesser PB, Lim R, Spratt DE, et al. The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positron emission tomography scan. Oral Oncol 2014;50:802-8
46. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
47. Bjurberg M, Henriksson E, Brun E, et al. Early changes in 2-deoxy-2-18F fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro. Cancer Biother Radiopharm 2009;24:327-32
48. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009;50(Suppl 1): 97S-105S
49. Isles MG, McConkey C, Mehanna HM. A systematic review and metaanalysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210-22
50. Marcus C, Ciarallo A, Tahari AK, et al. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. J Nucl Med 2014;55:1411-6
51. Hoshikawa H, Mori T, Yamamoto Y, et al. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer. Clin Nucl Med 2015;40:464-8
52. Troost EG, Bussink J, Hoffmann AL, et al. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 2010;51:866-74